CA19-9 and Apolipoprotein-A2 isoforms as detection markers for pancreatic cancer - a prospective evaluation.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Honda, KKatzke, V A
Hüsing, A
Okaya, S
Shoji, H
Onidani, K
Olsen, A
Tjønneland, A
Overvad, K
Weiderpass, E
Vineis, P
Muller, D
Tsilidis, K K
Palli, D
Pala, V
Tumino, R
Naccarati, A
Panico, S
Aleksandrova, K
Boeing, H
Bueno-de-Mesquita, H B
Peeters, P H
Trichopoulou, A
Lagiou, P
Khaw, K-T
Wareham, N J
Travis, R C
Merino, S
Duell, E J
Rodríguez-Barranco, M
Chirlaque, M D
Barricarte, A
Rebours, V
Boutron-Ruault, M-C
Romana Mancini, F
Brennan, P
Scelo, G
Manjer, J
Sund, M
Öhlund, D
Canzian, F
Kaaks, R
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
CA19-9 and Apolipoprotein-A2 isoforms as detection markers for pancreatic cancer - a prospective evaluation.Published in
Int J Cancer 2019; 144(8):1877-87Publiekssamenvatting
Recently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. This study provides a first prospective evaluation of an ApoA2 isoform ("ApoA2-ATQ/AT"), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma samples collected up to 60 months prior to diagnosis. The detection discrimination statistics were calculated for risk scores by strata of lag-time. For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer patients from cancer-free individuals were 0.80 for plasma taken ≤6 months before diagnosis, and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within >6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and ≤18 months (C = 0.75 vs. 0.74, p = 0.022). At 98% specificity, and for lag times of ≤6, >6-18 or ≤18 months, sensitivities were 57%, 36% and 43% for CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. 50%, 29% and 36% for CA19-9 alone. Compared to CA19-9 alone, the combination of CA19-9 and ApoA2-ATQ/AT may improve detection of pancreatic cancer up to 18 months prior to diagnosis under usual care, and may provide a useful first measure for pancreatic cancer detection prior to imaging. This article is protected by copyright. All rights reserved.PMID
30259989ae974a485f413a2113503eed53cd6c53
10.1002/ijc.31900
Scopus Count
Collections
Related articles
- Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes.
- Authors: Hayasaki A, Murata Y, Usui M, Hibi T, Fujii T, Iizawa Y, Kato H, Tanemura A, Azumi Y, Kuriyama N, Kishiwada M, Mizuno S, Sakurai H, Uchida K, Isaji S
- Issue date: 2019
- Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.
- Authors: Felix K, Honda K, Nagashima K, Kashiro A, Takeuchi K, Kobayashi T, Hinterkopf S, Gaida MM, Dang H, Brindl N, Kaiser J, Büchler MW, Strobel O
- Issue date: 2022 Mar 1
- Serum apolipoprotein A2 isoforms in autoimmune pancreatitis.
- Authors: Kobayashi T, Sato Y, Nishiumi S, Yagi Y, Sakai A, Shiomi H, Masuda A, Okaya S, Kutsumi H, Yoshida M, Honda K
- Issue date: 2018 Mar 11
- Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
- Authors: Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, Marsh T, Sanada M, Sasajima Y, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Miura N, Kamita M, Sakamoto T, Shoji H, Jung G, Srivastava S, Yamada T
- Issue date: 2015 Nov 9
- Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms.
- Authors: Honda K
- Issue date: 2022